CN114209650A - Process for improving content uniformity of ibuprofen suspension - Google Patents
Process for improving content uniformity of ibuprofen suspension Download PDFInfo
- Publication number
- CN114209650A CN114209650A CN202111601838.2A CN202111601838A CN114209650A CN 114209650 A CN114209650 A CN 114209650A CN 202111601838 A CN202111601838 A CN 202111601838A CN 114209650 A CN114209650 A CN 114209650A
- Authority
- CN
- China
- Prior art keywords
- mixed solution
- stirring
- solution
- ibuprofen
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a process for improving the content uniformity of an ibuprofen suspension, which comprises the following steps: A) adding soluble starch into water, stirring until the soluble starch is completely dissolved, and cooling to obtain a solution A; B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B; C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, and adding ibuprofen and pigment to obtain a mixed solution C; D) mixing the remaining 20% of sucrose and xanthan gum in the prescription amount with the mixed solution C to obtain a mixed solution D; E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E; F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension. The invention can eliminate the air bubbles caused by the high-speed running of the colloid mill by matching the suspension with a vacuum defoaming machine through the colloid mill, thereby ensuring that the content uniformity reaches the qualified range.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a process for improving content uniformity of ibuprofen suspension.
Background
Ibuprofen, also known as ibuprofen, was first synthesized in 1964 by Nicholson et al, uk, the company butz BOOTS, england, patented first and produced industrially. Ibuprofen is the only commonly recommended antipyretic for children by the world health organization and the FDA in the United states, and is a recognized first choice anti-inflammatory for children. Ibuprofen has antiinflammatory, analgesic, and antipyretic effects. The curative effect for treating rheumatism and rheumatoid arthritis is slightly inferior to that of acetylsalicylic acid and phenylbutazone. Is suitable for treating rheumatic arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, neuritis and the like.
Since the world, the medicine is far stronger than aspirin, phenylbutazone and paracetamol in anti-inflammatory, pain relieving and antipyretic effects, and is favored by consumers. In fact, ibuprofen makes a great contribution to relieving the patients from arthralgia, neuralgia, dysmenorrheal and other diseases caused by head and body pain after widely entering families. According to the data, the sale amount of ibuprofen is about twice as much as that of similar antipyretic analgesics.
Currently, ibuprofen suspension is marketed in China as ibuprofen suspension (trade name "Meilin", manufactured by Shanghai Qiangsheng pharmaceutical Co., Ltd.)
The ibuprofen belongs to a heterogeneous system in the preparation, xanthan gum, soluble starch and the like in the ibuprofen suspension have high viscosity, so that the uniform dispersion of the raw material medicines is influenced, and the phenomenon of nonuniform content is improved by the adding sequence of the raw material medicines and the adding mode of the xanthan gum in the process research.
However, the ibuprofen suspension has too high viscosity, and the ibuprofen raw material drug still has agglomeration after being added, so the solution preparation process needs to be further improved.
Disclosure of Invention
The invention aims to provide a process for improving the content uniformity of ibuprofen suspension, which is simple in process, low in cost and stable in product quality.
The invention provides a process for improving the content uniformity of an ibuprofen suspension, which comprises the following steps:
A) adding soluble starch into water at the temperature of 90-100 ℃, stirring until the soluble starch is completely dissolved, and cooling to 40-50 ℃ to obtain a solution A;
B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A in sequence, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B;
C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, adding ibuprofen and pigment, and continuously stirring for 30-40 min to obtain a mixed solution C;
D) mixing the residual sucrose and xanthan gum with the prescription amount of 20% with water, stirring until the xanthan gum is completely swelled, and mixing with the mixed solution C to obtain a mixed solution D;
E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E;
F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension.
Preferably, the composition comprises, by weight, 20 parts of ibuprofen, 3.6 parts of xanthan gum, 100 parts of glycerol, 13.1 parts of soluble starch, 300 parts of sucrose, 2.2 parts of anhydrous citric acid, 800.8 parts of polysorbate, 2.0 parts of sodium benzoate, 0.024 part of pigment and 1.2 parts of essence.
Preferably, the pressure of the vacuum defoaming is 0.3-1.0 MPa; the vacuum defoaming time is 0.5-2 hours.
Preferably, the time of the colloid mill is 0.5-2 hours.
Preferably, the pigment is sunset yellow and/or allura red.
Preferably, the essence is orange essence and/or strawberry essence.
The invention provides a process for improving the content uniformity of an ibuprofen suspension, which comprises the following steps: A) adding soluble starch into water at the temperature of 90-100 ℃, stirring until the soluble starch is completely dissolved, and cooling to 40-50 ℃ to obtain a solution A; B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A in sequence, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B; C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, adding ibuprofen and pigment, and continuously stirring for 30-40 min to obtain a mixed solution C; D) mixing the residual sucrose and xanthan gum with the prescription amount of 20% with water, stirring until the xanthan gum is completely swelled, and mixing with the mixed solution C to obtain a mixed solution D; E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E; F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension. The ibuprofen suspension is uniformly dispersed into a heterogeneous system by passing through the colloid mill, but a large amount of bubbles are generated in the colloid mill which rotates at a high speed in the process of passing through the colloid mill.
Detailed Description
The invention provides a process for improving the content uniformity of an ibuprofen suspension, which comprises the following steps:
A) adding soluble starch into water at the temperature of 90-100 ℃, stirring until the soluble starch is completely dissolved, and cooling to 40-50 ℃ to obtain a solution A;
B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A in sequence, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B;
C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, adding ibuprofen and pigment, and continuously stirring for 30-40 min to obtain a mixed solution C;
D) mixing the residual sucrose and xanthan gum with the prescription amount of 20% with water, stirring until the xanthan gum is completely swelled, and mixing with the mixed solution C to obtain a mixed solution D;
E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E;
F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension.
The process of the invention uses the following raw materials in parts by weight:
20 parts of ibuprofen, 3.6 parts of xanthan gum, 100 parts of glycerol, 13.1 parts of soluble starch, 300 parts of sucrose, 2.2 parts of anhydrous citric acid, 800.8 parts of polysorbate, 2.0 parts of sodium benzoate, 0.024 part of pigment and 1.2 parts of essence.
The method comprises the steps of firstly adding purified water into a liquid preparation tank I, heating to 90-100 ℃ while stirring, then adding soluble starch, stirring for 20-25 min until the starch is completely dissolved, and cooling to 40-50 ℃.
Then adding glycerin, anhydrous citric acid, polysorbate 80 and sodium benzoate in sequence, and stirring for 20-25 min to completely dissolve the materials.
And slowly adding 80% of sucrose according to the formula amount, continuously stirring for 20-25 min after the addition is finished until the sucrose is completely dissolved, then sequentially adding ibuprofen, sunset yellow, allura red and other pigments, and continuously stirring for 30-40 min.
Adding purified water into the liquid preparation tank II, adding the rest of sucrose with the amount of 20% of the prescription amount and the xanthan gum with the total prescription amount, stirring and mixing for 30-40 min until the sucrose is completely dissolved and the xanthan gum is completely swelled, pouring the mixture into the liquid preparation tank I, mixing with the mixed liquid added with the ibuprofen, and uniformly stirring.
And then cooling the system to below 30 ℃, adding essence such as strawberry essence, orange essence and the like, supplementing a proper amount of purified water, and stirring for 5-10 min to obtain a suspension.
And (3) passing the obtained suspension through a colloid mill, dispersing the liquid medicine, adding appropriate purified water, re-colloid milling, transferring the washed purified water into a liquid preparation tank, and fixing the volume.
In the invention, the time for passing through the colloid mill is preferably 0.5-2 hours, and more preferably 1-1.5 hours.
And (4) defoaming the suspension dispersed by the colloid mill in vacuum to obtain the ibuprofen suspension.
In the present invention, the pressure for defoaming in vacuum is preferably 0.3 to 1.0Mpa, such as 0.3Mpa, 0.4Mpa, 0.5Mpa, 0.6Mpa, 0.7Mpa, 0.8Mpa, 0.9Mpa, 1.0Mpa, and is preferably a range value having any of the above values as an upper limit or a lower limit.
In the vacuum defoaming process, the too small pressure cannot achieve the effect of corresponding change of content uniformity, the suspension system of the product can be damaged due to too large defoaming pressure, the problem of damage of the suspension system can be well solved under the control pressure of 0.3-1.0 MPa, and the damage of the suspension system can cause the uneven viscosity reduction content.
The time for vacuum defoaming is preferably 0.5 to 2 hours, and more preferably 1 to 1.5 hours. The suspension system is damaged due to too long defoaming time, the stability is checked, the viscosity is reduced, and the content uniformity cannot be met due to too short defoaming time. The requirements of stability and content uniformity can be met only by perfectly matching the vacuum defoaming time and the pressure.
The process of passing through the colloid mill can ensure that the indissolvable drug is dispersed in suspension more uniformly, the particle size of the raw material drug can reach a state more favorable for dissolution under the action of the colloid mill, the colloid mill with high-speed shearing can ensure that the drug also generates a large amount of bubbles, and the bubbles can be reduced through vacuum defoaming, so that the content uniformity of the drug in the suspension is improved.
The invention provides a process for improving the content uniformity of an ibuprofen suspension, which comprises the following steps: A) adding soluble starch into water at the temperature of 90-100 ℃, stirring until the soluble starch is completely dissolved, and cooling to 40-50 ℃ to obtain a solution A; B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A in sequence, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B; C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, adding ibuprofen and pigment, and continuously stirring for 30-40 min to obtain a mixed solution C; D) mixing the residual sucrose and xanthan gum with the prescription amount of 20% with water, stirring until the xanthan gum is completely swelled, and mixing with the mixed solution C to obtain a mixed solution D; E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E; F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension. The ibuprofen suspension is uniformly dispersed into a heterogeneous system by passing through the colloid mill, but a large amount of bubbles are generated in the colloid mill which rotates at a high speed in the process of passing through the colloid mill.
In order to further illustrate the present invention, the following examples are provided to describe the process of the present invention for improving the content uniformity of ibuprofen suspension in detail, but should not be construed as limiting the scope of the present invention.
Example 1
The preparation process of ibuprofen suspension comprises the following steps
(1) Weighing purified water, pouring into a liquid preparation tank I, and heating to about 100 ℃ while stirring
(2) Adding soluble starch, stirring for 20min, and dissolving completely. Cooling to 40-50 deg.C
(3) Sequentially adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate, cleaning the materials in beaker with appropriate amount of purified water, stirring for 20min, dissolving completely
(4) Slowly adding sucrose 80% of the prescription amount, stirring for 20min, stirring to dissolve completely, sequentially adding ibuprofen, sunset yellow and allura red, and stirring for 40min
(5) Weighing purified water, pouring into a liquid preparation tank II, adding the rest 20% of sucrose and the xanthan gum (manually mixing for 10min), stirring for 30min until the sucrose is completely dissolved and the xanthan gum is completely swelled, pouring into a liquid preparation tank I, and stirring uniformly
(6) Cooling the solution to below 30 deg.C, adding orange essence and strawberry essence, supplementing appropriate amount of purified water, stirring for 5min
Passing through a colloid mill, adding appropriate purified water, re-colloid milling, transferring the washed purified water to a liquid preparation tank, and fixing the volume.
Defoaming in vacuum at 0.5MPa for 1 hr.
Comparative example 1
(1) Weighing purified water, pouring into a liquid preparation tank I, and heating to about 100 ℃ while stirring
(2) Adding soluble starch, stirring for 20min, and dissolving completely. Cooling to 40-50 deg.C
(3) Sequentially adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate, cleaning the materials in beaker with appropriate amount of purified water, stirring for 20min, dissolving completely
(4) Slowly adding sucrose 80% of the prescription amount, stirring for 20min, stirring to dissolve completely, sequentially adding ibuprofen, sunset yellow and allura red, and stirring for 40min
(5) Weighing purified water, pouring into a liquid preparation tank II, adding the rest 20% of sucrose and the xanthan gum (manually mixing for 10min), stirring for 30min until the sucrose is completely dissolved and the xanthan gum is completely swelled, pouring into a liquid preparation tank I, and stirring uniformly
(6) Cooling the solution to below 30 deg.C, adding orange essence and strawberry essence, supplementing appropriate amount of purified water, stirring for 5min
Adding water to constant volume and stirring for 5 min.
Comparative example 2
An ibuprofen suspension was prepared as in example 1, except that the vacuum degassing time was 1 hour and the pressure was 0.2 MPa.
Content uniformity comparison results
Table 1 example and comparative example content uniformity results
The results show that: the solution after vacuum defoaming by a colloid mill obviously improves the content uniformity, and the RSD value is obviously reduced.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (6)
1. A process for improving content uniformity of ibuprofen suspension comprises the following steps:
A) adding soluble starch into water at the temperature of 90-100 ℃, stirring until the soluble starch is completely dissolved, and cooling to 40-50 ℃ to obtain a solution A;
B) adding glycerol, anhydrous citric acid, polysorbate 80 and sodium benzoate into the solution A in sequence, and stirring until the glycerol, the anhydrous citric acid, the polysorbate 80 and the sodium benzoate are completely dissolved to obtain a solution B;
C) adding 80% of sucrose in the formula amount into the solution B), stirring and dissolving, adding ibuprofen and pigment, and continuously stirring for 30-40 min to obtain a mixed solution C;
D) mixing the residual sucrose and xanthan gum with the prescription amount of 20% with water, stirring until the xanthan gum is completely swelled, and mixing with the mixed solution C to obtain a mixed solution D;
E) cooling the temperature of the mixed solution D to be below 30 ℃, adding essence, and stirring to obtain a mixed solution E;
F) and sequentially passing the mixed solution E through a colloid mill and defoaming in vacuum to obtain the ibuprofen suspension.
2. The process according to claim 1, wherein the ibuprofen composition comprises, by weight, 20 parts of ibuprofen, 3.6 parts of xanthan gum, 100 parts of glycerol, 13.1 parts of soluble starch, 300 parts of sucrose, 2.2 parts of anhydrous citric acid, 800.8 parts of polysorbate, 2.0 parts of sodium benzoate, 0.024 part of pigment and 1.2 parts of essence.
3. The process as claimed in claim 2, wherein the pressure of the vacuum defoaming is 0.3-1.0 MPa; the vacuum defoaming time is 0.5-2 hours.
4. The process according to claim 3, wherein the colloid mill is used for 0.5 to 2 hours.
5. The process according to claim 4, wherein the pigment is sunset yellow and/or allura red.
6. The process according to claim 5, wherein the essence is orange essence and/or strawberry essence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111601838.2A CN114209650B (en) | 2021-12-24 | 2021-12-24 | Process for improving content uniformity of ibuprofen suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111601838.2A CN114209650B (en) | 2021-12-24 | 2021-12-24 | Process for improving content uniformity of ibuprofen suspension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114209650A true CN114209650A (en) | 2022-03-22 |
| CN114209650B CN114209650B (en) | 2023-04-18 |
Family
ID=80705702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111601838.2A Active CN114209650B (en) | 2021-12-24 | 2021-12-24 | Process for improving content uniformity of ibuprofen suspension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114209650B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624523A (en) * | 2022-10-27 | 2023-01-20 | 华润三九（南昌）药业有限公司 | Preparation method of ibuprofen suspension |
| CN115770218A (en) * | 2022-12-28 | 2023-03-10 | 福建太平洋制药有限公司 | Preparation process for improving content uniformity of ibuprofen suspension |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347411A (en) * | 2008-08-29 | 2009-01-21 | 扬州市三药制药有限公司 | Ibuprofen suspension and method of preparing the same |
| CN106390528A (en) * | 2015-08-03 | 2017-02-15 | 安徽华明制药有限公司 | Vacuum bubble-removing apparatus used in preparation of enteral nutritional emulsion |
| CN110025572A (en) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | Lauroyl Aripiprazole suspension and preparation method thereof |
| CN112402383A (en) * | 2020-10-28 | 2021-02-26 | 北京哈三联科技有限责任公司 | Preparation method of risperidone freeze-dried tablet and product thereof |
| CN112516083A (en) * | 2020-12-15 | 2021-03-19 | 太阳升(亳州)生物医药科技有限公司 | Ibuprofen suspension and preparation method thereof |
| US20210353573A1 (en) * | 2018-10-08 | 2021-11-18 | Chanelle Pharmaceuticals Manufacturing Ltd. | A soft-gel capsule formulation, method of manufacture and use thereof |
-
2021
- 2021-12-24 CN CN202111601838.2A patent/CN114209650B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347411A (en) * | 2008-08-29 | 2009-01-21 | 扬州市三药制药有限公司 | Ibuprofen suspension and method of preparing the same |
| CN106390528A (en) * | 2015-08-03 | 2017-02-15 | 安徽华明制药有限公司 | Vacuum bubble-removing apparatus used in preparation of enteral nutritional emulsion |
| CN110025572A (en) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | Lauroyl Aripiprazole suspension and preparation method thereof |
| US20210353573A1 (en) * | 2018-10-08 | 2021-11-18 | Chanelle Pharmaceuticals Manufacturing Ltd. | A soft-gel capsule formulation, method of manufacture and use thereof |
| CN112402383A (en) * | 2020-10-28 | 2021-02-26 | 北京哈三联科技有限责任公司 | Preparation method of risperidone freeze-dried tablet and product thereof |
| CN112516083A (en) * | 2020-12-15 | 2021-03-19 | 太阳升(亳州)生物医药科技有限公司 | Ibuprofen suspension and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨宝进等主编: "《现代食品加工学》", 30 September 2006, 北京：中国农业大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624523A (en) * | 2022-10-27 | 2023-01-20 | 华润三九（南昌）药业有限公司 | Preparation method of ibuprofen suspension |
| CN115624523B (en) * | 2022-10-27 | 2023-09-26 | 华润三九（南昌）药业有限公司 | Preparation method of ibuprofen suspension |
| CN115770218A (en) * | 2022-12-28 | 2023-03-10 | 福建太平洋制药有限公司 | Preparation process for improving content uniformity of ibuprofen suspension |
| CN115770218B (en) * | 2022-12-28 | 2023-10-10 | 福建太平洋制药有限公司 | Preparation technology for improving content uniformity of ibuprofen suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114209650B (en) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114209650B (en) | Process for improving content uniformity of ibuprofen suspension | |
| CN102382013A (en) | Preparation method of carbasalate calcium | |
| CN104323987B (en) | Mequindox injection and preparation method thereof | |
| CN113209041A (en) | New formula hydroxypropyl methylcellulose hollow capsule and preparation method thereof | |
| CN112516083A (en) | Ibuprofen suspension and preparation method thereof | |
| CN112552196A (en) | Method for preparing aspirin-lysine | |
| CN105769795B (en) | A kind of Chinese holly Desloratadine freeze-drying oral instant-dissolving tablet and preparation method thereof | |
| CN104045743B (en) | A kind of preparation method of fine work dalteparin sodium | |
| CN102343093B (en) | Seaweed polysaccharide medicinal plant film coating and preparation method thereof | |
| CN109422642B (en) | Refining method of benzoic acid, production method and equipment of pharmaceutical grade sodium benzoate | |
| CN105688223A (en) | Preparation process of small-grain-diameter microcrystalline cellulose pellets | |
| CN106336525B (en) | Plant hollow capsule tailing redissolution method | |
| CN113004429B (en) | Refining method of carboxyl ferric maltose | |
| CN104586813A (en) | All-starch plant capsules and production method thereof | |
| CN107488238A (en) | A kind of extracting method of red seaweed polysaccharide | |
| CN101822822A (en) | Drug composition of pramlintide and preparation method thereof | |
| CN104557715A (en) | Preparation method of imidocarb dipropionate sterile APIs (active pharmaceutical ingredients) | |
| CN113087818A (en) | Dextran sulfate sodium salt or potassium salt and production method thereof | |
| CN114209655B (en) | Preparation method of dolutegravir micropowder | |
| CN111170879A (en) | Small-particle-size pregabalin and preparation method thereof | |
| CN111187164A (en) | 6-carbonyl-8-chloro ethyl caprylate synthesis device and method for synthesizing 6-carbonyl-8-chloro ethyl caprylate by using same | |
| CN117860669A (en) | Hysterin injection and preparation method thereof | |
| CN108309985A (en) | A kind of anticancer pharmaceutical composition | |
| CN115770218B (en) | Preparation technology for improving content uniformity of ibuprofen suspension | |
| CN116672321A (en) | Production process for improving quality of valsartan tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |